Lotronex withdrawn from market.
D002243:Carbolines / Q000009:adverse effects*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D017277:Drug Approval; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron